Methamphetamine Use Disorder
45
11
13
17
Key Insights
Highlights
Success Rate
85% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
6.7%
3 terminated out of 45 trials
85.0%
-1.6% vs benchmark
2%
1 trials in Phase 3/4
41%
7 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 17 completed trials
Clinical Trials (45)
Transcranial Magnetic Stimulation for Methamphetamine Use Disorder During Pregnancy
Tirzepatide for Obesity and Meth Use Disorder
A Pilot Study of Transcranial Magnetic Stimulation Plus Episodic Future Thinking for Methamphetamine Use Disorder
Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder
Psilocybin for Methamphetamine Use Disorder
Implementing a Contingency Management Program Addressing Methamphetamine Use for and With the People of Hawai'i
Theta Burst Stimulation in the Management of Methamphetamine Use Disorder in Indonesia
Screen, Treat and Retain People With Primary Meth Use Disorder at MMT Clinics
ECG Findings in Methamphetamine Use
LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis
CHAMPION: Combining HIV And Meth Prevention and Treatment Interventions Optimized for HIV-Negative MSM
An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder
Closed-loop TBS Targeting rPO for the Core Clinical Features of the Methamphetamine Use Disorder
Closed-loop TMS for the Core Clinical Features of the Methamphetamine Use Disorder
Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV
Psilocybin Therapy for Methamphetamine Use Disorder and HIV
Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study
Cerebellum-Prefrontal Paired-Pulse Stimulation for Methamphetamine Use Disorder
Methamphetamine and Troriluzole
Non-Abstinence Outcomes in Methamphetamine Use Disorder